IS HSP70 A THERAPEUTIC TARGET FOR PARKINSON'S DISEASE?

• Jon Olano-Bringas,
• Patricia Villegas-Zafra,
• Begum Kurt,
• Dalila Ciceri,
• Arturo Muga,
• Nora Bengoa-Vergniory

Affiliations

Jon Olano-Bringas

Achucarro Basque Center for Neuroscience, Laboratory Of Aggregation And Glial Response, Leioa, Spain

Patricia Villegas-Zafra

Achucarro Basque Center for Neuroscience, Laboratory Of Aggregation And Glial Response, Leioa, Spain

Begum Kurt

Achucarro Basque Center for Neuroscience, Laboratory Of Aggregation And Glial Response, Leioa, Spain

Dalila Ciceri

Achucarro Basque Center for Neuroscience, Laboratory Of Aggregation And Glial Response, Leioa, Spain

Arturo Muga

Biofisika Institute (CSIC-UPV/EHU), Biochemistry And Molecular Biology, Leioa, Spain

Nora Bengoa-Vergniory

Achucarro Basque Center for Neuroscience, Laboratory Of Aggregation And Glial Response, Leioa, Spain; Ikerbasque, Basque Foundation For Science, Bilbao, Spain; University of the Basque Country (UPV/EHU), Department Of Neuroscience, Leioa, Spain; University of Oxford, Oxford Parkinson’s Disease Centre And Department Of Physiology, Anatomy And Genetics, Oxford, United Kingdom